In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes

Gene Therapy

Volumn 3, Issue 11, 1996, Pages 965-972

  Clemens, P R ^a   Kochanek, S ^b   Sunada, Y ^c   Chan, S ^b   Chen, H H ^a   Campbell, K P ^c   Caskey, C T ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenoviral vector; Duchenne muscular dystrophy; Dystrophin; Gene transfer

Indexed keywords

COMPLEMENTARY DNA; CREATINE KINASE; DYSTROPHIN; RECOMBINANT PROTEIN; UTROPHIN;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SKELETAL MUSCLE;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; DYSTROPHIN; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; TUMOR CELLS, CULTURED;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 0029857641     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Zubrzycka-Gaarn EE et al The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988; 333: 466-469.
3. Arahata K et al. Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. Proc Natl Acad Sci USA 1989; 86: 7154-7158.
4. Engel AG, Yamamoto M, Fischbeck KH. Dystrophinopathies. In: Engel AG, Franzini-Armstrong C (eds). Myology. McGraw-Hill: New York, 1994, pp 1133-1187.
5. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-629.
6. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
7. England SB et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343: 180-182.
8. Clemens PR et al. Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Hum Gene Ther 1995; 6: 1477-1485.
9. Phelps SF et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-1258.
10. Wells DJ et al Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995; 4: 1245-1250.
11. Ragot T et al Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-650.
12. Vincent N et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993; 5: 130-134.
13. Alameddine HS et al. Expression of a recombinant dystrophin in mdx mice using adenovirus vector. Neuromusc Disord 1994; 4: 193-203.
14. Dai Y et al. Cellular and humoral immune responses to adeno-viral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
15. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
16. Hoffman EP, Morgan JE, Watkins SC, Partridge TA. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neural Sci 1990, 99. 9-25.
17. Tripathy SK et al Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91. 11557-11561.
18. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 1995; 2: 107-115.
19. Ghadge GD et ai. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Therapy 1995; 2: 132-137.
20. Vilquin J-T et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
21. Yang Y et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
22. Wolff JA et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
23. Kozarsky KF et al Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54-62.
24. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adeno-virus vectors. Nature Med 1996; 2: 545-550.
25. MacGregor GR, Mogg AE, Burke JF, Caskey CT. Histochemical staining of clonal mammalian cell lines expressing E. coli β-galactosidase indicate heterogeneous expression of the bacterial gene. Somat Cell Mol Genet 1987; 13: 253-265.
26. Hoffman EP et al. Cross-reactive protein in Duchenne muscle Lancet 1989; ii: 1211-1212.
27. Koenig M, Kunkel LM. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem 1990; 265: 4560-4566.
28. Roberds SL, Anderson RD, Ibraghimov-Beskrovnaya O, Campbell KP. Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin). J Biol Chem 1993; 268: 23739-23742.
29. Ibraghimov-Beskrovnaya O et al. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992; 355: 696-702.
30. Yang B et al. Heterogeneity of the 59-kDa dystrophin-associated protein revealed by cDNA cloning and expression. J Biol Chem 1994; 269: 6040-6044.